Characteristic | Â | Number (%) | Median | Range |
---|---|---|---|---|
Sex | Â | Â | Â | Â |
 | Male | 1 (9%) |  |  |
 | Female | 10 (91%) |  |  |
Subgroups | Â | Â | Â | Â |
 | Oligoarthritis | 5 (46%) |  |  |
 | RF-negative polyarthritis | 2 (18%) |  |  |
 | Undifferentiated arthritis | 2 (18%) |  |  |
 | Enthesitis related arthritis | 1 (9%) |  |  |
 | Systemic | 1 (9%) |  |  |
Age at injection, years | Â | Â | 12.5 | 2-16 |
Disease duration, years | Â | Â | 4.8 | 0.8-13.5 |
Number of joints (n = 15) with | Â | Â | Â | Â |
 | Swelling | 13 (87%) |  |  |
 | Pain | 14 (93%) |  |  |
 | Limited range of motion | 15 (100%) |  |  |
 | Active arthritis | 15 (100%) |  |  |
VAS wrist pain patient/parent, cm | Â | Â | 4.0 | 0.2-6.0 |
VAS global assessment patient/parent, cm | Â | Â | 0.5 | 0-3.7 |
VAS global assessment physician, cm | Â | Â | 2.9 | 1.5-7.2 |
CRP level, mg/l | Â | Â | 3 | 0-22 |
ESR, mm/h | Â | Â | 15 | 4-48 |
HLA B27 positive, number of patients | Â | 2 (18%) | Â | Â |
ANA positive, number of patients | Â | 4 (36%) | Â | Â |
RF positive, number of patients | Â | 1 (9%) | Â | Â |
Drug therapies | Â | Â | Â | Â |
 | MTX | 5 (45%) |  |  |
 | MTX + Etanercept | 1 (9%) |  |  |
 | MTX + Systemic corticosteroids | 1 (9%) |  |  |